Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca Hints At Acquisitions, Merck And Novo Nordisk React To China Cuts – Emerging Market Earnings Roundup (Part 3)

This article was originally published in PharmAsia News

Executive Summary

AstraZeneca plans to enhance capacity in emerging markets while cutting jobs and consolidating operations. Merck sees strong volume growth in China, and Novo Nordisk reports a slow quarterly sales growth in the Chinese human insulin market.

You may also be interested in...



AstraZeneca Goes Virtual In Neuroscience R&D As Part Of Workforce Reduction

AstraZeneca is to slash 12% of its workforce in the next three years, as the company forecasts declining revenues in 2012 because of its steep patent cliff, government pricing interventions and R&D pipeline failures.

GSK Sees Enduring Pricing Pressure Unlikely, Novo Projects Lower Growth In China, Lilly Bolsters Diabetes Presence In India: Emerging Markets Round Up (Part 1)

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets. In Q3, earnings in emerging markets were slightly down for GlaxoSmithKline PLC, Novo Nordisk A/S, and Eli Lilly & Co, mostly due to increased pricing pressure as well as increased competition in the diabetes market, with local players rapidly gaining market share..

AstraZeneca Invests $200 Million For Manufacturing Plant In China Medical City

AstraZeneca PLC has announced a plan to invest $200 million to build a new manufacturing plant inside Taizhou, Jiangsu-based China Medical City

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC080468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel